Advertisement

Topics

The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients

2016-08-15 09:39:13 | BioPortfolio

Published on BioPortfolio: 2016-08-15T09:39:13-0400

Clinical Trials [138 Associated Clinical Trials listed on BioPortfolio]

Rh-Endostatin (Endostar®) Continuous Intravenous Infusion

Endostar is a anti-angiogenesis product and has been launched in China . The efficacy and safety have been defined. However, the compliance is unsatisfactory since routine i.v of Endostar ...

Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical

The purpose of this study is to determine whether Endostar pumping into vein with Thalidomide are more effective in the treatment of Advanced Colorectal Cancer (ACRC).

FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer

FOLFOX4 plus Avastin has been suggested as firstline regimen for advanced colorectal cancer by NCCN, a new angiogenesis inhibitor, known as Endostar(Recombinant Human Endostatin), prolonge...

Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma

The role of angiogenesis has been less clear in lymphoma than in solid tumors, in part related to the heterogeneity of disease and technical issues. In addition to vascular endothelial gro...

Impact of Endostar Combined With Chemotherapy on the Angiogenesis of Advanced Non-Small Cell Lung Cancer (NSCLC)

To study the impact of endostar combined with docetaxel and cisplatin on the angiogenesis of non-small cell lung cancer, patients will be randomly assigned to the group one (endostar combi...

PubMed Articles [741 Associated PubMed Articles listed on BioPortfolio]

The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.

The overall survival (OS) in non-small cell lung cancer (NSCLC) is poor, with median OS of advanced NSCLC with standard systemic chemotherapy being reported at 13.6 months and the 5-year survival rate...

Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases.

Angiogenesis is a critical step in the progression of almost all human malignancies and some other life-threatening diseases. Anti-angiogenic therapy is a novel and effective approach for treatment of...

N-Acetylcysteine Suppresses LPS-Induced Pathological Angiogenesis.

Angiogenesis is a key feature during embryo development but is also part of the pathogenesis of cancer in adult life. Angiogenesis might be modulated by inflammation.

Angiogenesis: focusing on the effects of exercise in aging and cancer.

Although it is known that exercise induces angiogenesis, a clear mechanism has remained elusive due to various experimental limitations. This review presents the current status of angiogenesis-related...

Sulforaphane rescues the ethanol-suppressed angiogenesis through oxidative- and ER-stress in chick embryos.

Our previous study showed that ethanol exposure inhibited embryonic angiogenesis mainly due to the excessive stimulation of reactive oxygen species (ROS) production. In this study, we investigated whe...

Medical and Biotech [MESH] Definitions

Agents that induce or stimulate the PHYSIOLOGIC ANGIOGENESIS process. This is caused by a number of ANGIOGENIC PROTEINS.

Agents that modulate the PHYSIOLOGIC ANGIOGENESIS process. This is accomplished by endogenous ANGIOGENIC PROTEINS and a variety of other chemicals and pharmaceutical agents.

Intercellular signaling peptides and proteins that regulate the proliferation of new blood vessels under normal physiological conditions (ANGIOGENESIS, PHYSIOLOGICAL). Aberrant expression of angiogenic proteins during disease states such as tumorigenesis can also result in PATHOLOGICAL ANGIOGENESIS.

Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.

Proteins that specifically inhibit the growth of new blood vessels (ANGIOGENESIS, PHYSIOLOGIC).

More From BioPortfolio on "The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial